Morgan Stanley upgrades DexCom (DXCM), cites undervalued recovery and G7 margin potential

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...
Seeking Alpha

DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

Investors in DexCom (NASDAQ:DXCM) have unfortunately lost 43% over the last three years

DexCom, Inc. ( NASDAQ:DXCM ) shareholders should be happy to see the share price up 12% in the last month. But ...
TipRanks on MSN

Dexcom price target raised to $78 from $75 at Mizuho

Mizuho raised the firm’s price target on DexCom (DXCM) to $78 from $75 and keeps an Outperform rating on the shares. The firm ...
Nasdaq

DexCom price target raised to $90 from $80 at BofA

BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...
Nasdaq

DexCom Stock Just Fell to a 5-Year Low. Is It a No-Brainer Buy at This Price?

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
Yahoo Finance

Does DexCom’s Recent 5% Jump Signal a Real Value Opportunity for 2025?

Wondering if DexCom stock is a hidden bargain or just riding a wave? You are not alone, and today's market swings only add to the intrigue. DexCom shares have jumped 5.4% over the past week even after ...
Investing

DexCom stock price target maintained at $100 by TD Cowen ahead of Q3 results

Investing.com - TD Cowen has reiterated its Buy rating on DexCom (NASDAQ:DXCM) with a price target of $100.00 ahead of the company’s third-quarter earnings report, scheduled for October 30. According ...
Business Insider

DexCom price target raised to $100 from $90 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on DexCom (DXCM) to $100 from $90 and keeps an Overweight rating on the shares. The firm notes the company reported full Q4 results, ...
Seeking Alpha

DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...
The Motley Fool

Why DexCom Stock Dove by 5% Today

A Raymond James analyst cut his price target on the specialty medical device maker. It was the second such price target cut so far this month. Raymond James prognosticator Jayson Bedford was the ...